~~<i id='005A74C103'><strike id='005A74C103'><tt id='005A74C103'><pre id='005A74C103'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

explore

comprehensive

author：explore 2025-09-05 18:29:49 - browse：8998

A European regulatory panel has recommended against approval of a lung cancer drug made by Mirati Therapeutics, the company said Friday.

Mirati said it will appeal the negative opinion of the drug, called Krazati, issued by a committee of the European Medicines Agency that met this week. But for now, the adverse decision is likely to be adopted by European regulators and prevent the company from marketing the pill in Europe.

Krazati works by blocking a specific type of KRAS alteration called G12C, found in approximately 13% of lung tumors.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Affirmative action in medical school literally saved lives
Next article： Live blog: Hearing on CRISPR

explore

knowledge

explore

focus

explore

leisure time

JanetJacksonrecentlyannouncedsheispregnantatage49.FrancoisNel/GettyImagesHertourmightbecalledUnstopp

WSS

Readout LOUD podcast: The Sarepta saga, decoding biotech hype

Donald Trump's relentless attacks on special counsel Jack Smith

With FDA staff opposed to Sarepta therapy, top official intervened

In Gaza, a nonprofit 3D prints tourniquets and stethoscopes

In areas with more Black doctors, Black people live longer

After Sarepta trial failure, Duchenne families brace for more debate

explore

comprehensive

explore

Walensky prepares to leave CDC — and Congress — behind

New guidelines on severe brain injury complicate already difficult decisions

Medicare details structure of new drug price negotiation program

Life sciences investors close nearly $6 billion in new funds

Malaria cases in Florida and Texas: Here’s what you need to know

Donald Trump's relentless attacks on special counsel Jack Smith

New air purifier tech could be key to improving indoor air quality

Explaining an after

What does generative AI mean for health care? We asked experts

Paxlovid study fails to answer questions over benefit for broader groups

knowledge

The strategy behind pharma's lawsuits over drug pricing reform

How neuroscience research could help beat back brain cancer

FDA grants conditional OK to Sarepta’s gene therapy for Duchenne

Key Senate panel to consider PBM, drug pricing reform package

Explaining an after

Life sciences investors close nearly $6 billion in new funds

explore

focus

explore

leisure time